1-20 of 5,029 results for subject:Diabetes
Librarians' tools
- Search time
- 0.365 seconds
- Solr query time
- 0.012 seconds
- Search query
- subject:Diabetes
- We searched for
- subject_t:Diabetes OR subject_ses:9636
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what steps he is taking to to ensure continuity of leadership for early-stage type 1 diabetes policy and service development during the transition of functions from NHS England to his Department.
To ask the Secretary of State for Health and Social Care, what steps he is taking to to ensure continuity of leadership for early-stage type 1 diabetes policy and service development during the transition of functions from NHS England to his Department.
The proposed abolition of NHS England and the associated transfer of its functions is subject to legislation and the will of Parliament. We are engaging with partners inside and outside the organisations as the process to design the future Department continues.
NHS England will continue to carry out its existing responsibilities and statutory functions during the transition period.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS bodies regarding a future screening programme for early-stage type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS bodies regarding a future screening programme for early-stage type 1 diabetes.
The Government is guided by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. It is only where the UK NSC is confident that there is robust evidence that to screen would provide more good than harm that a screening programme is recommended, as all medical interventions carry an inherent risk.
The UK NSC received a submission via its 2024 open call process to consider screening for autoimmune type 1 diabetes through blood testing. Now that the National Institute for Health and Care Excellence has published its recommendation on the drug teplizumab, the UK NSC will look again at this open call submission and consider whether a fresh review of the evidence for type 1 diabetes screening should be undertaken.
The UK NSC is aware of the Early Surveillance for Autoimmune Diabetes study and looks forward to receiving the results of this study when the trial is complete.
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the introduction of teplizumab contributes to reducing rates of diabetic ketoacidosis at diagnosis and inequalities in outcomes for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the introduction of teplizumab contributes to reducing rates of diabetic ketoacidosis at diagnosis and inequalities in outcomes for people with type 1 diabetes.
Teplizumab is a new treatment for people aged eight years old and over with stage 2 type 1 diabetes, before the onset of symptoms. Its introduction represents a significant development in the treatment of type 1 diabetes and requires new clinical pathways and service arrangements to support safe and equitable access.
NHS England is working with integrated care boards, clinicians, patient groups, charities, and industry partners to support the development of these pathways. This work is already underway and is focused on helping local systems prepare for implementation and supporting consistent access across the country.
Evidence considered by the National Institute for Health and Care Excellence indicates that teplizumab can delay progression to stage 3 type 1 diabetes by almost three years on average. This gives people and their families additional time to understand the condition, prepare for future treatment and monitoring needs, and engage with clinical support before symptoms develop. Earlier identification and planned clinical management may help reduce the risk of diabetic ketoacidosis at diagnosis.
Integrated care boards will be required to make teplizumab available to all eligible individuals within the statutory 90 day implementation period. NHS England will continue to provide national leadership, including through a community of practice to share learning, support implementation, and ensure that health inequalities are identified and addressed appropriately.
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the UK's position globally in respect of research into beta cell preservation, regeneration and replacement therapies for type 1 diabetes.
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the UK's position globally in respect of research into beta cell preservation, regeneration and replacement therapies for type 1 diabetes.
Through UK Research and Innovation (UKRI), including UKRI’s Medical Research Council (MRC), the Government supports a broad portfolio of research relevant to Type 1 diabetes. This includes work on pancreatic biology, immunology, and cell replacement approaches, alongside wider research into the underlying mechanisms of the disease. Funding is awarded through open, competitive processes based on scientific excellence, ensuring the UK remains well placed to contribute to advances in areas such as beta cell therapies.
The Department of Health and Social Care also funds research through the National Institute for Health and Care Research, which supports high-quality research to improve the diagnosis, treatment and management of Type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the...
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the...
The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.
Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.
The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.
The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help accelerate the translation of beta cell research into clinical trials and routine NHS care for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help accelerate the translation of beta cell research into clinical trials and routine NHS care for people with type 1 diabetes.
The Department delivers research into type 1 diabetes through the National Institute for Health and Care Research (NIHR).
As well as funding research itself, the Department invests significantly in centres of excellence which support and deliver health and care research. Collectively these form the NIHR infrastructure.
NIHR infrastructure supports research to help accelerate the development of treatments for type 1 diabetes. This includes, for example, research into earlier diagnosis and improved risk prediction to identify people who may benefit from disease-modifying or beta cell-preserving therapies. It also includes support for the development and testing of beta cell replacement, stem cell-derived islet, and immune-modulating therapies.
The NIHR infrastructure provides the end-to-end system needed to design, test, and deliver new therapies, playing a central role in delivery of clinical trials and ensuring that effective innovations are supported into practice at scale.
The NIHR is also supporting a new United Kingdom-wide Type 1 Diabetes Cell Therapy Clinical Trials Network. Funded by the Type 1 Diabetes Grand Challenge, this £5 million NIHR-backed programme aims to build a nationwide infrastructure across NIHR Biomedical Research Centres and Clinical Research Facilities for cell-therapy trials. This network is designed to address shared challenges in delivering cell therapy trials, ensuring all people with the condition gain access to the latest cutting-edge treatments as early as possible.
Motion that this House has considered the matter of reducing levels of premature deaths from heart disease and stroke. Agreed to on question.
Motion that this House has considered the matter of reducing levels of premature deaths from heart disease and stroke. Agreed to on question.
I beg to move,
That this House has considered the matter of reducing levels of premature deaths from heart disease and stroke.
It is an honour to serve under your chairmanship, Dame Siobhain. I thank hon. Members for attending the debate.
Cardiovascular disease remains one of the United Kingdom’s biggest killers and one...
I beg to move,
That this House has considered the matter of reducing levels of premature deaths from heart disease and stroke.
It is an honour to serve under your chairmanship, Dame Siobhain. I thank hon. Members for attending the debate.
Cardiovascular disease remains one of the United Kingdom’s biggest killers and one...
My hon. Friend is making an important and passionate speech, especially in the light of the personal circumstances that he mentioned. I agree with him about deprivation. Does he agree that access to fresh, affordable food is incredibly important, particularly in the most deprived areas? In Castlemilk in my constituency,...
My hon. Friend is making an important and passionate speech, especially in the light of the personal circumstances that he mentioned. I agree with him about deprivation. Does he agree that access to fresh, affordable food is incredibly important, particularly in the most deprived areas? In Castlemilk in my constituency,...
I absolutely agree. If we could get fresh food to more of our communities and young people, it would have a massive positive effect on dealing with CVD—that must be dealt with.
This debate could not be more timely. The Government have rightly identified CVD as one of the UK’s biggest...
I absolutely agree. If we could get fresh food to more of our communities and young people, it would have a massive positive effect on dealing with CVD—that must be dealt with.
This debate could not be more timely. The Government have rightly identified CVD as one of the UK’s biggest...
It is a pleasure to speak in this important debate about preventing premature death from heart disease and stroke. I congratulate the hon. Member for South Ribble (Mr Foster) on securing the debate and introducing it so ably. It is courageous of him to talk about the medical challenges that...
It is a pleasure to speak in this important debate about preventing premature death from heart disease and stroke. I congratulate the hon. Member for South Ribble (Mr Foster) on securing the debate and introducing it so ably. It is courageous of him to talk about the medical challenges that...
It is a pleasure to serve under your chairship, Dame Siobhain. I am grateful to my hon. Friend the Member for South Ribble (Mr Foster) for securing this important debate and for his opening remarks on his own health. We all wish him well.
My speech today will focus on heart...
It is a pleasure to serve under your chairship, Dame Siobhain. I am grateful to my hon. Friend the Member for South Ribble (Mr Foster) for securing this important debate and for his opening remarks on his own health. We all wish him well.
My speech today will focus on heart...
It is a pleasure to serve under your chairship, Dame Siobhain. I thank the hon. Member for South Ribble (Mr Foster) for setting the scene incredibly well on a subject that affects all of us. As always, I will give some stats for Northern Ireland, where unfortunately we seem to...
It is a pleasure to serve under your chairship, Dame Siobhain. I thank the hon. Member for South Ribble (Mr Foster) for setting the scene incredibly well on a subject that affects all of us. As always, I will give some stats for Northern Ireland, where unfortunately we seem to...
The hon. Gentleman is, as always, generous with his time. We all fully appreciate the slant that he brings from Northern Ireland. Would he agree that there is also the issue of regional inequalities within England? We see in Yorkshire and the north of England some of the worst rates...
The hon. Gentleman is, as always, generous with his time. We all fully appreciate the slant that he brings from Northern Ireland. Would he agree that there is also the issue of regional inequalities within England? We see in Yorkshire and the north of England some of the worst rates...
The hon. Gentleman always sums up the thrust of the debate in his interventions; he has outlined that there is sometimes a postcode lottery. He is also right to underline that in areas with deprivation where the emphasis on health is probably less, the issues and the number of those...
The hon. Gentleman always sums up the thrust of the debate in his interventions; he has outlined that there is sometimes a postcode lottery. He is also right to underline that in areas with deprivation where the emphasis on health is probably less, the issues and the number of those...
As chair of the all-party parliamentary group for diabetes, I should say that we have been pushing to make sure that, when people with diabetes have those diabetic care processes, those are better linked with other comorbidities and ancillary services. Does he agree that we need to see more of...
As chair of the all-party parliamentary group for diabetes, I should say that we have been pushing to make sure that, when people with diabetes have those diabetic care processes, those are better linked with other comorbidities and ancillary services. Does he agree that we need to see more of...
I certainly do; the hon. Gentleman and I most definitely agree about that.
The tragedy is that so much of this premature loss of life is entirely preventable; if it can be prevented, then we should be doing more. The British Heart Foundation reports that half of all strokes and heart...
I certainly do; the hon. Gentleman and I most definitely agree about that.
The tragedy is that so much of this premature loss of life is entirely preventable; if it can be prevented, then we should be doing more. The British Heart Foundation reports that half of all strokes and heart...
It is a pleasure to serve under your chairship, Dame Siobhain. I congratulate my near-neighbour and hon. Friend the Member for South Ribble (Mr Foster) on securing this important debate. I wish him well. I also congratulate the right hon. Member for Rayleigh and Wickford (Mr Francois) on achieving the...
It is a pleasure to serve under your chairship, Dame Siobhain. I congratulate my near-neighbour and hon. Friend the Member for South Ribble (Mr Foster) on securing this important debate. I wish him well. I also congratulate the right hon. Member for Rayleigh and Wickford (Mr Francois) on achieving the...
I am sorry to disappoint the hon. Gentleman, not least as he is being so kind to me, but for the record it is my wife’s bat-phone, not mine.
I am sorry to disappoint the hon. Gentleman, not least as he is being so kind to me, but for the record it is my wife’s bat-phone, not mine.